Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
Aon plc (NYSE: AON) has announced a strategic investment in eMed Population Health, Inc., a company specializing in GLP-1 programs for obesity treatment. The investment follows Aon's successful implementation of eMed's GLP-1 weight management program for its U.S. workforce, which demonstrated impressive results with 22.4 pounds average weight loss and a 95% retention rate among 1,200+ participants over six months.
The partnership aims to scale eMed's digital-first healthcare platform, which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support. This strategic move aligns with Aon's broader initiative to develop comprehensive GLP-1 solutions and advisory capabilities for employers seeking to address obesity and chronic conditions through medication-based interventions.
Aon plc (NYSE: AON) ha annunciato un investimento strategico in eMed Population Health, Inc., realt脿 specializzata in programmi a base di GLP-1 per il trattamento dell'obesit脿. L'operazione segue il successo dell'implementazione, presso la forza lavoro statunitense di Aon, del programma di gestione del peso GLP-1 di eMed: oltre 1.200 partecipanti hanno registrato una perdita media di 22,4 libbre in sei mesi, con un tasso di ritenzione del 95%.
La partnership punta a scalare la piattaforma sanitaria digitale di eMed, che integra diagnostica domiciliare, screening con supervisione, prescrizioni guidate da clinici e supporto continuo per l鈥檃derenza. Questa mossa strategica si inserisce nell'iniziativa pi霉 ampia di Aon di sviluppare soluzioni GLP-1 e competenze consulenziali per i datori di lavoro interessati a contrastare obesit脿 e malattie croniche tramite interventi farmacologici.
Aon plc (NYSE: AON) ha anunciado una inversi贸n estrat茅gica en eMed Population Health, Inc., una compa帽铆a especializada en programas con GLP-1 para el tratamiento de la obesidad. La inversi贸n llega despu茅s del 茅xito de Aon al implementar el programa de manejo de peso con GLP-1 de eMed entre su plantilla en EE. UU.: m谩s de 1.200 participantes obtuvieron una p茅rdida media de 22,4 libras en seis meses y un 铆ndice de retenci贸n del 95%.
La alianza busca escalar la plataforma sanitaria digital de eMed, que combina diagn贸stico en casa, cribados supervisados, prescripci贸n guiada por cl铆nicos y apoyo continuo para la adherencia. Esta decisi贸n estrat茅gica est谩 alineada con la iniciativa m谩s amplia de Aon para desarrollar soluciones GLP-1 y capacidades de asesor铆a dirigidas a empleadores que desean abordar la obesidad y enfermedades cr贸nicas mediante intervenciones farmacol贸gicas.
Aon plc (NYSE: AON)臧� GLP-1 旮半皹 牍勲 旃橂 頂勲攴鸽灗鞚� 鞝勲鞙茧 頃橂姅 eMed Population Health, Inc.鞐� 鞝勲灥鞝� 韴瀽毳� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 韴瀽電� Aon鞚� 鞛愳偓 氙戈淡 歆侅洂 雽�靸�(eMed鞚� GLP-1 觳挫 甏�毽� 頂勲攴鸽灗)鞚� 靹标车鞝侅溂搿� 霃勳瀰頃� 雿� 霐半ジ 瓴冹溂搿�, 6臧滌洈 霃欖晥 1,200氇� 鞚挫儊鞚� 彀胳棳鞛愲摛鞚� 韽夑窢 22.4韺岇毚霌�鞚� 觳挫 臧愳唽鞕� 95% 鞙犾鞙�鞚� 氤挫榾鞀惦媹雼�.
鞏戩偓電� 臧�鞝� 瓴�靷�, 臧愲弲鞛� 欤茧弰 鞀ろ伂毽嫕, 鞛勳儊鞚橁皜 鞎堧偞頃橂姅 觳橂癌, 歆�靻嶌爜鞚� 氤奠暯 靾滌潙 歆�鞗愳潉 瓴绊暕頃� eMed鞚� 霐旍韯� 鞖办劆 項姢旒�鞏� 頂岆灚韽检潉 頇曥灔頃橂姅 瓴冹潉 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟. 鞚� 鞝勲灥鞝� 臁办箻電� 鞎诫 旮半皹 臧滌瀰鞚� 韱淀暣 牍勲 氚� 毵岇劚 歆堩櫂鞚� 頃搓舶頃橂牑電� 瓿犾毄欤茧ゼ 鞙勴暅 膦呿暕鞝侅澑 GLP-1 靻旊（靺橁臣 鞛愲 鞐焿鞚� 臧滊皽頃橂牑電� Aon鞚� 甏戨矓鞙勴暅 鞚措媹靺旐嫲敫岇檧 鞚检箻頃╇媹雼�.
Aon plc (NYSE: AON) a annonc茅 un investissement strat茅gique dans eMed Population Health, Inc., une entreprise sp茅cialis茅e dans les programmes 脿 base de GLP-1 pour le traitement de l'ob茅sit茅. Cet investissement fait suite 脿 la mise en 艙uvre r茅ussie par Aon du programme de gestion du poids GLP-1 d鈥檈Med aupr猫s de ses employ茅s aux 脡tats-Unis : plus de 1 200 participants ont enregistr茅 une perte moyenne de 22,4 livres en six mois, avec un taux de r茅tention de 95%.
Le partenariat vise 脿 d茅ployer 脿 grande 茅chelle la plateforme de sant茅 num茅rique d鈥檈Med, qui combine diagnostics 脿 domicile, d茅pistages supervis茅s, prescriptions encadr茅es par des cliniciens et soutien continu 脿 l'adh茅sion au traitement. Cette initiative strat茅gique s'inscrit dans la d茅marche plus large d鈥橝on visant 脿 d茅velopper des solutions GLP-1 et des capacit茅s de conseil pour les employeurs souhaitant traiter l'ob茅sit茅 et les maladies chroniques par des interventions m茅dicamenteuses.
Aon plc (NYSE: AON) hat eine strategische Beteiligung an eMed Population Health, Inc. bekanntgegeben, einem Unternehmen, das auf GLP-1-Programme zur Behandlung von Fettleibigkeit spezialisiert ist. Die Investition folgt auf Aons erfolgreiche Einf眉hrung des GLP-1-Gewichtsmanagementprogramms von eMed f眉r die US-Belegschaft: 脺ber 1.200 Teilnehmende verzeichneten innerhalb von sechs Monaten einen durchschnittlichen Gewichtsverlust von 22,4 Pfund und eine 95%ige Bindungsrate.
Die Partnerschaft zielt darauf ab, die digital orientierte Gesundheitsplattform von eMed zu skalieren, die Heimdiagnostik, proctor-gest眉tzte Screenings, von Klinikerinnen und Klinikern begleitete Verschreibungen sowie kontinuierliche Adh盲renzunterst眉tzung kombiniert. Dieser strategische Schritt passt zu Aons umfassender Initiative, GLP-1-L枚sungen und Beratungsleistungen f眉r Arbeitgeber zu entwickeln, die mittels medikament枚ser Interventionen Adipositas und chronische Erkrankungen angehen wollen.
- Successful pilot program showed 22.4 pounds average weight loss with 95% retention rate
- Over 1,200 participants enrolled in Aon's GLP-1 program within six months
- Strategic investment will help scale eMed's digital healthcare platform to reach more employers
- Partnership expected to help reduce long-term employer health costs
- High costs associated with GLP-1 medications require strategic consideration from employers
Insights
Aon's strategic investment in eMed strengthens its position in the lucrative GLP-1 market with proven results from internal implementation.
Aon's investment in eMed Population Health represents a strategic move to capitalize on the rapidly growing GLP-1 weight management market. After successfully implementing eMed's GLP-1 program for its own U.S. workforce, Aon has seen compelling results that validate this investment decision: 1,200 registrants, an average weight loss of
This partnership is particularly significant as it follows Aon's recent multi-year analysis of U.S. commercial health claims data regarding GLP-1 medications, giving the company both data-driven insights and now direct implementation experience in this space. By investing in eMed, Aon positions itself to capitalize on the growing employer demand for effective obesity management solutions while potentially reducing their clients' long-term healthcare costs.
The investment allows Aon to expand beyond its traditional professional services model into the healthcare solutions space, creating a new revenue stream with significant growth potential. For context, the GLP-1 market is experiencing explosive growth as these medications move beyond diabetes treatment into mainstream weight management applications. Aon is strategically placing itself at the intersection of employer benefits management and healthcare delivery innovation.
The company appears to be building a comprehensive GLP-1 strategy with "complementary solutions" and "advisory capabilities" that could strengthen its competitive position in the benefits consulting space while addressing a major healthcare cost driver for its clients.
Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings
The investment follows the launch earlier this year of Aon's subsidized GLP-1 weight management benefit program for its
With this investment, eMed will continue to increase distribution of its digital-first healthcare platform 鈥� which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support鈥攖o reach more employers and patients.
"As the leader of Aon's People Organization, I know how important it's been to include GLP-1 coverage as part of our own
Stevens added: "This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace in helping employers reduce long-term health costs while improving the quality of life for their people. By aligning innovation with behavior change and accountability, together we can deliver sustainable results at scale."
The collaboration marks a major milestone in eMed's mission to deliver effective and sustainable care through an integrated, data-driven experience, while expanding its provider network, behavioral health tools and market reach.
"Today marks a game-changing partnership between Aon and eMed and is a win for both payers and participants," said Linda Yaccarino, CEO of eMed Population Health, Inc. "Our shared vision of market transformation is validated and accelerated by the investment from Aon. This strategic investment in eMed further enables our firm to play an active role in offering a differentiated global solution focused on medication adherence 鈥� helping employers reduce long-term health costs while improving quality of life for their people."
Aon continues to build a complimentary suite of GLP-1 solutions, industry-leading experience and advisory capabilities for clients. In April, Aon听 from its multi-year analysis of
"The rise of GLP-1 medications and its cost has sparked significant strategic considerations from employers looking to address obesity and other chronic conditions," said Farheen Dam, Head of Health for
About eMed
eMed庐 is the world's first end-to-end GLP-1 care platform built on Empathetic AI鈩�. From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at .听
About Aon
听(狈驰厂贰:听AON) exists to shape decisions for the better 鈥� to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.
Follow Aon on鈥�,鈥�,鈥�贵补肠别产辞辞办鈥�补苍诲鈥�.鈥疭tay up-to-date by visiting Aon's鈥� and sign up for news alerts鈥�.
Media Contacts
eMed
Matt Gorman
[email protected]
Aon
[email protected]
Toll-free (
International: +1 312 381 3024听
听
View original content to download multimedia:
SOURCE Aon plc
FAQ
What are the results of Aon's GLP-1 weight management program in 2025?
Why did Aon (NYSE: AON) invest in eMed Population Health?
What services does eMed's digital-first healthcare platform offer?
How is Aon addressing the GLP-1 medication trend for employers?
What was the enrollment rate for Aon's GLP-1 program in 2025?
